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Abstract
Background: Although Malassezia genusare part of the skin normal flora, under certain conditions, they become pathogenic.
Catheter-related fungemia, caused by Malassezia, which is associated with biofilm formation, is considered a nosocomial infection.
Objectives: The aim of this study was to evaluate the ability of Malassezia globosa and Malassezia restricta in biofilm formation.
Methods: Biofilm formation was carried out using catheter segments in 12-well plates. Results were measured using 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) colorimetric assay in 96-well plates. The data was analyzed using
univariate Analysis of Variance (ANOVA) or Repeated Measures ANOVA. P values of ≤ 0.05 were considered statistically significant.
Statistical analyses were performed using IBM SPSS Statistics version 22.0 software.
Results: Both M. globosa and M. restricta species were able to form biofilms in vitro. Malassezia restricta was more capable than M.
globosa to form biofilms, yet, significant differences were not observed (P = 0.192).
Conclusions: Over time, Malassezia biofilms matured. Due to the above species ability in forming biofilm, they could play an im-
portant role in fungemia that should be considered in therapeutic procedures.
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1. Background
Malassezia biofilm is produced by a community of
these bacteria, alone or mixed with other microorganisms,
which are attached to the living and non-living surfaces
and are difficult to separate from surfaces. This structure
has physical and chemical resistance, and resistance to an-
timicrobial agents is almost 2000 times higher compared
with planktonic cells. Biofilm of Malassezia is a structure
that is organized as single-layer or multi-layer of blasto-
conidia. Biofilms, with the ability of producing an extracel-
lular matrix, acts as a barrier against the influence of drugs
(1-5). Although Malassezia genus is part of the skin nor-
mal flora, under certain conditions, becomes pathogenic
and in the recent years has been reported as an emerging
pathogen (1, 6-9). The ability of these fungi in coloniza-
tion on the catheter is associated with biofilm formation.
Catheters are frequently used in new medical devices, es-
pecially at the Intensive Care Unit (ICU) and their use may
lead to local or systemic infection (1, 5, 10-12). Since noso-
comial infections effect approximately 10% to 30% of pa-
tients at the ICU and are associated with significant mortal-
ity, it should be noted that a significant proportion of these
infections are due to biofilm formation (5, 10-12); how-
ever, fungal biofilms have been studied less than bacterial
biofilms. Most studies are about Candida (13-16), however,
there have been only a few studies on Malassezia biofilms
(1, 4, 5, 13, 17).
2. Objectives
The aim of this study was to evaluate the ability
of Malassezia globosa and Malassezia restricta species in
biofilm formation.
3. Methods
After preparing the standard species of M. restricta (CBS
7877) and M. globosa (CBS 7966) from the Institute (Cen-
traalbureau voor Schimmelcultures, Utrecht,The Nether-
lands), the study was conducted at the Medical mycology
laboratory, faculty of Medical Sciences, Tarbiat Modares
University.
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3.1. Evaluation of Biofilm Formation
Catheter segments of Certofix® Mono V 420 central ve-
nous catheter (B. Braun, Milano, Italy) with 1 × 1 cm di-
mensions were prepared in 12-well plates (Nalge Nunc In-
ternational, NY, USA). After suspension of the Malassezia
yeast in a concentration of 106 CFU/mL Phosphate Buffered
Saline (PBS, PH = 7.2 - 7.4) biofilm was formed using the
medium modified Dixon broth (made of 3.6 g malt extract
(Merck, Germany), 0.6 g mycological peptone, 2 g dried
beef bile (Sigma, UK), 1 mL Tween 40 (Merck, Germany), 0.2
mL glycerol (Merck, Germany), 0.2 mL oleic acid (Merck,
Germany), 5 mg chloramphenicol, 50 mg cycloheximide
and 100 mL distilled water) (13). The test wells were selected
and catheter segments were divided in doubled form and
incubated in fetal bovine serum (FBS) for 24 hours (h) at
37°C on a rocker. Next, catheter segments were placed in
new 12-well plates and 4 mL of culture medium mDixon
broth containing Malassezia yeast at a concentration of 106
CFU/mL, was poured in each well to submerge catheter seg-
ments and then they were incubated in a 75 rpm (round per
minute) shaking incubator for 24 hours at 32°C for cell at-
tachment to the catheter surface. After a period of time,
to separate the loose and non-binding cells (planktonic
cells), catheter segments were washed with PBS and 4 mL
of culture medium mDixon broth containing 100 mM of
glucose was added to the wells (4, 18). After incubation at
32°C for 48, 96, and 144 hours in a 75 rpm shaking incu-
bator (5), catheter segments were removed from wells and
formed biofilms on the surfaces were scraped by a plastic
spatula (cell scraping) and were poured in 96-well micro-
plates (Nalge Nunc International, NY, USA). After addition
of 50 µL of distilled water and 10 µL MTT (Sigma Chemi-
cal Co., St Louis, MO, USA) at a concentration of 5 mg/mL,
they were incubated for 4 hours at 32°C. Finally, by adding
50 µL of Dimethyl Sulfoxide (DMSO) solution to all wells
and incubation for 10 minutes at 32°C, the percentage of
attached cells on the surface of the catheter segments was
measured by using the enzyme linked immunosorbent as-
say (ELISA) absorbance reader (Stat Fax 2000, USA) at 540
nm. In this method, the well containing catheter segments
with mDixon broth medium and without yeast cell suspen-
sion was used as a negative control.
3.2. Evaluation of Biofilm Formation on the Catheter Segments
Through Scanning Electron Microscopy (SEM)
Two catheter segments with biofilms formed on them
after 96 hours were studied with a scanning electron mi-
croscope according to a previously described method (4)
(Leo, Cambridge, UK).
3.3. Statistical Analysis
Normality of data was assessed using the One-Sample
Kolmogorov-Smirnov Test (with Lilliefors Significance
Correction). After collecting and classifying the data,
they were analyzed using univariate analysis of variance
(ANOVA) or repeated measures ANOVA. A value of P ≤
0.05 was considered statistically significant. Statistical
analyses were performed using IBM SPSS Statistics version
22 software (19).
4. Results
Both M. globosa and M. restricta species were able to
form in vitro biofilms. At three time points, Malassezia
biofilm matured and had a linier increase. Optical den-
sity (OD) results of biofilm formation after periods of 48,
96 and 144 hours are shown in Figure 1. Malassezia restricta
was more capable than M. globosa to form a biofilm, yet, be-
tween them, a significant difference was not observed (P =
0.192). Figure 2 shows the SEM results of two M. globosa and
M. restricta species.
Figure 1. Comparison of the Ability to Form Biofilms by Malassezia restricta and
Malassezia globosa at Three Time Points
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Significant differences were not observed between the two species during the above
time points (P = 0.192).
5. Discussion
Catheter-related fungemia caused by Malassezia is re-
ported in premature infants, immune compromised chil-
dren, adults with parenteral nutrition, and individuals
with immune deficiency (13). Reports show the role of
Malassezia in catheter-related biofilm formation and its
pathogenicity in etiology of infections, such as fungemia
(5, 13, 20-22). In this study, M. globosa and M. restricta species
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Figure 2. Scanning Electron Microscopy Showing Biofilm Structures of A, M. globosa and B, M. restricta
were used to evaluate the in vitro ability of biofilm forma-
tion on catheter surfaces.
One of the common and standard methods to evaluate
biofilm formation is the assessment of cells viability after
treatment with antifungal drugs. A vital MTT dye could be
used for this purpose. The MTT test is a semi-quantitative
colorimetric method to measure cell viability (23, 24). This
method was used in the current study.
In this study, both M. globosa and M. restricta species
were able to form in vitro biofilms. Malassezia restricta was
more capable than M. globosa to form a biofilm and after
periods of 48, 96 and 144 hours, the OD results of M. restricta
wells were more than M. globosa wells. However, between
them, significant differences were not observed (P = 0.192,
Figure 1). This study shows that the two M. globosa and M.
restricta species could form in vitro biofilm, similar to M.
pachydermatis species (4, 5). According to this study and
other laboratory and clinical studies (4, 5, 13), it has been
concluded that Malassezia species are able to form biofilms
in two in vivo and in vitro models and give rise to nosoco-
mial infections in children and adults.
Biofilm formation by microorganisms, including
fungi varies with time (5, 10, 18, 25). In this study, biofilm
mass (OD value) had a linear increase as time increased,
which is in accordance with the study of Cannizzo (5).
In comparison with mature biofilms of Candida that are
formed within 48 hours, the Malassezia biofilm requires 4
days to mature and the structure of Malassezia biofilm is
simpler than Candida. Attachment and nutritional prop-
erties of Malassezia may be the cause of this difference
(5).
There are a few studies about biofilm formation of
Malassezia species and reports are often about M. pachyder-
matis. However, there is not enough information available
regarding other species. In this study, to evaluate biofilm
formation, two M. globosa and M. restricta species were used
for the pilot study. These species were standard strains and
in terms of the ability to form biofilms (OD value) could
be different from results of clinical isolates. According to
previous studies, most of the isolates (95%), regardless of
the area of isolation being a skin lesion or normal skin,
were capable to form biofilms, yet their quantity was vari-
able among different strains (4, 5). Also, genotypic stud-
ies have shown that the ability to form biofilms and their
quantity could be variable among different genotypes (4).
Strain dependence of biofilm formation that has been pre-
viously suggested for Candida, could be due to physiologi-
cal and pathological characteristics of yeast and in the case
of Malassezia could be dependent on phospholipase activ-
ity (4). On the other hand, clinically, Malassezia coloniza-
tion on the catheter could vary in different wards of the
hospital (13). Therefore, due to differences in the ability and
quantity of biofilm formation among Malassezia strains
and genotypes, although, the in vitro model conditions of
biofilm formation are not very different from in vivo sit-
uation (26), future comprehensive studies on clinical iso-
lates of Malassezia with more samples are suggested to de-
termine whether colonization and biofilm formation is re-
lated to clinical findings of patients.
5.1. Conclusion
Both M. globosa and M. restricta species were able to
form in vitro biofilms. Over time, Malassezia biofilms had
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matured. Due to the two above-mentioned species abil-
ity in forming biofilms, they could play an important role
in fungemia and this should be considered in therapeutic
procedures.
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